PuraCap Pharmaceutical Acquires Blu Pharmaceuticals and Blu Caribe
SAN JUAN – Puracap Pharmaceutical has announced the acquisition of Blu Pharmaceutical LLC and Blu Caribe Inc., creating PuraCap International, a joint venture between PuraCap and Dangdai International Group Co. The acquisition will expand PuraCap’s manufacturing beyond soft gelatin capsules to include oral tablet & capsule dosage forms for the the U.S. and global markets.
“This acquisition is a major step in the growth of our capability in the manufacturing of oral solid dosage forms in the United States, which complements our state-of-the-art soft gelatin capsule manufacturing facility in Wuhan, China,” Puracap Pharmaceutical CEO Dahai Guo said in the published announcement.
The acquisition includes a 145,000-square-foot manufacturing facility in Dorado, as well as an 185,000-square-foot warehouse & distribution center in Franklin, Kentucky.
PuraCap’s corporate structure includes prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC and private label brands (PuraCap International).
Wuhan Dangdai Science & Technology Industries (Group) Co. is a China-based privately held conglomerate. Its portfolio comprises several Chinese publicly listed entities and private companies in North America and Africa, including biopharmaceuticals, media, entertainment, real estate development, tourism, agriculture, textile and financial services.